TIDMCOG

RNS Number : 3270D

Cambridge Cognition Holdings PLC

19 October 2022

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

GBP1.1 million eCOA contract win for rare blood disease trial

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a GBP1.1m contract with a major pharmaceutical company to provide electronic clinical outcome assessments ("eCOA") and hardware for a rare blood disease study running over the next two years. The new contract, with an existing customer, is for a mixture of eCOA licenses, services and hardware to support an upcoming clinical trial.

As a leader in digital outcome assessments, Cambridge Cognition primarily provides cognitive measures and eCOA solutions for clinical trials in central nervous systems disorders. Impressed by Cambridge Cognition's expertise and performance in handling multi-site-multi-language studies, the customer has selected the Company to be the eCOA provider for this trial. This recognition is important for the Company as the provision of eCOA for clinical trials is a sizeable growth market, valued at over US$1bn per annum and growing at more than 15% according to market research(1) .

Cambridge Cognition has been contracted to provide the platform and the hardware for capturing participants' experiences as well as their responses to standardised questionnaires and scales. Cambridge Cognition's experienced clinical project management team will work closely with the customer to ensure successful use of the software and devices.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Cambridge Cognition has a strong history of delivering cognitive assessments in the field, traditionally in clinics and now also at home. We are pleased to see this new order from an existing client, our reputation for quality, service and scientific rigour is enabling us to win eCOA-only clinical trials."

References

   1.     GrandView Research 2018 eCOA Report

For further information, contact:

 
 Cambridge Cognition Holdings Plc               Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer         press@camcog.com 
  Stephen Symonds, Chief Financial Officer 
 Panmure Gordon (UK) Limited (NOMAD and Joint   Tel: 020 7886 2500 
  Broker)                                        (Corporate Finance) 
  Freddy Crossley / Emma Earl                    (Corporate Broking) 
  Rupert Dearden 
 Dowgate Capital Limited (Joint Broker)         Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)         Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTEAXEPFLKAFFA

(END) Dow Jones Newswires

October 19, 2022 02:00 ET (06:00 GMT)

Cambridge Cognition (AQSE:COG.GB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Cambridge Cognition.
Cambridge Cognition (AQSE:COG.GB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Cambridge Cognition.